Amphastar 制药
AMPH
25.87
-0.55
-2.08%
Amphastar 制药
US · AMPH
#3194 按市值排名
25.87
-0.55
-2.08%
实时 - 追踪5344个代码 - 心跳于24秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
增持
- 最近一期(2026/Q3)披露持股的机构数量增加了1家。
- 机构持股总比例上升了0.2个百分点。
机构持股
- 机构持股比例
- 84.13% +0.17pp
- 机构数量
- 266 +1
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向分歧机构在上一报告期增持了股份,同时该股在最近20个交易日的主力资金呈净流出——两者方向出现分歧。
机构持股变动数据按季度发布且存在滞后;资金流向数据为每日更新。请将其作为方向性的交叉验证参考,而非精确的择时信号。
持股人类型
Mutual Fund53.97%
Private Company17.94%
Individual/Insider10.36%
Hedge Fund8.05%
Public Company2.31%
Government Pension Fund1.17%
Family Office/Trust0.39%
Insurance Company0.24%
Other5.54%
主要股东 截至 2026-03-31
Applied Physics & Chemistry Laboratories, Inc.
16.05% · 6.83M 股
BlackRock
12.28% · 5.22M 股
Yongfeng Zhang
6.28% · 2.67M 股
Dimensional Fund Advisors
5.42% · 2.31M 股
Vanguard Capital Management, LLC
4.01% · 1.71M 股
State Street Global Advisors
3.86% · 1.64M 股
American Century Investment Management
2.77% · 1.18M 股
Ziping Luo
2.62% · 1.11M 股
Marshall Wace LLP
2.51% · 1.07M 股
Geode Capital Management, LLC
2.28% · 969.84K 股
条形长度是相对于此处列出的最大股东而言,并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 23次买入 · 27次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Applied Physics & Chemistry Laboratories, Inc. | -- | 16.05% |
| Yongfeng Zhang | Co-founder, President, CEO, Chief Scientific Officer & Director | 6.28% |
| Ziping Luo | Chairman of the Board, Chief Scientist & COO | 2.62% |
| Rong Zhou | Senior Executive Vice President of Production | 0.48% |
| Shiren S. Lee | Independent Director | 0.36% |
| William Peters | CFO, Executive VP of Finance, Treasurer & Director | 0.16% |
| Floyd Petersen | Independent Director | 0.16% |
| Jacob Liawatidewi | Executive VP of Sales, Marketing & Corporate Administration Center, Corporate Secretary and Director | 0.15% |
| Michael Zasloff | Independent Director | 0.06% |
| Richard Prins | Lead Independent Director | 0.05% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-20 | William Peters | CFO, Executive VP of Finance, Treasurer & Director | Automatic Disposition | -4,139 | $25.00 |
| 2026-09-15 | Rong Zhou | Senior Executive Vice President of Production | Derivative Exercise and Sale | -10,000 | $13.35–23.94 |
| 2026-09-01 | Rong Zhou | Senior Executive Vice President of Production | Open Market Disposition | -3,187 | $23.63 |
| 2026-08-31 | Rong Zhou | Senior Executive Vice President of Production | Intent to Sell (Form 144) | -13,187 | $22.00 |
| 2026-08-10 | Richard Prins | Lead Independent Director | Open Market Disposition | -7,973 | $20.30 |
| 2026-08-06 | William Peters | CFO, Executive VP of Finance, Treasurer & Director | Automatic Disposition | -3,127 | $22.48 |
| 2026-08-06 | William Peters | CFO, Executive VP of Finance, Treasurer & Director | Derivative Exercise and Sale | -5,053 | $19.79–22.48 |
| 2026-07-08 | Anthony Pierce | Independent Director | Other Acquisition | +7,886 | -- |
| 2026-07-08 | Anthony Pierce | Independent Director | Other Derivative Acquisition | +16,646 | $19.02 |
| 2026-06-01 | Shiren S. Lee | Independent Director | Sale to Issuer | -769 | $18.45 |
| 2026-05-31 | Michael Zasloff | Independent Director | Other Acquisition | +8,143 | -- |
| 2026-05-31 | Michael Zasloff | Independent Director | Other Derivative Acquisition | +17,365 | $18.42 |
| 2026-05-31 | Richard Prins | Lead Independent Director | Other Acquisition | +8,143 | -- |
| 2026-05-31 | Richard Prins | Lead Independent Director | Other Derivative Acquisition | +17,365 | $18.42 |
| 2026-05-31 | Shiren S. Lee | Independent Director | Other Acquisition | +8,143 | -- |
| 2026-05-31 | Shiren S. Lee | Independent Director | Other Derivative Acquisition | +17,365 | $18.42 |
| 2026-05-31 | Gayle Deflin | Independent Director | Other Acquisition | +8,143 | -- |
| 2026-05-31 | Gayle Deflin | Independent Director | Other Derivative Acquisition | +17,365 | $18.42 |
| 2026-05-31 | David Gaugh | Director | Other Acquisition | +8,143 | -- |
| 2026-05-31 | David Gaugh | Director | Other Derivative Acquisition | +17,365 | $18.42 |
Form 4 申报记录,每家公司显示最新的一批。"Other Derivative Acquisition"(其他衍生品获取)类目多为限制性股票/期权归属,并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:05 · 仅供参考,不构成投资建议,也未考虑您的具体情况。
Amphastar 制药 讨论区 0 条评论